{"filings":[{"id":2364317,"accession_number":"0001437749-26-028590","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-08-20T11:04:58+00:00","items":["8.01"],"status":"ready","headline":"UroGen secures exclusive option to license IntraGel's TumoCure for head and neck cancer; invests up to $7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On Aug 18, 2026, UroGen U.S. entered an Option and Research License Agreement with IntraGel Therapeutics for TumoCure (head and neck cancer).","UroGen obtained exclusive option for worldwide license to develop/commercialize TumoCure using IntraGel's SRGel biodegradable hydrogel platform.","Also obtained options for additional SRGel-based products with UroGen-designated compounds, plus non-exclusive research license.","UroGen agreed to invest up to $7,000,000 in IntraGel equity via Securities Purchase Agreement on same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2061278,"accession_number":"0001437749-26-025793","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-08-05T12:02:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q2 2026: ZUSDURI revenue $50.4M (+73% QoQ); net loss narrows to $14.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $72.5M (Q2 2026) vs $24.2M (Q2 2025), driven by ZUSDURI launch.","ZUSDURI net product revenue $50.4M, 73% QoQ growth; 1,444 activated sites, 452 prescribers.","JELMYTO revenue $22.0M (Q2 2026) vs $24.2M (Q2 2025); FY guidance $97-101M.","Net loss $14.4M ($0.28/share) vs $49.9M ($1.05) in Q2 2025; cash $108.0M.","UGN-103 NDA on track for Q3 2026; new patent allowance extends ZUSDURI protection to July 2044."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1222396,"accession_number":"0001437749-26-021442","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-06-23T20:14:22+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"UroGen shareholders approve 1M share equity plan increase, re-elect all directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved 2017 Equity Incentive Plan amendment adding 1,000,000 ordinary shares to the reserve.","All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.","Advisory vote on executive compensation approved (25.1M for, 3.2M against).","PricewaterhouseCoopers LLP ratified as independent auditor for upcoming year (36.8M for).","Articles of Association amended to align shareholder proposal eligibility with Israeli Companies Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787961,"accession_number":"0001437749-26-019102","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-06-02T12:04:53+00:00","items":["8.01"],"status":"ready","headline":"UroGen settles patent litigation with Teva over Jelmyto; generic entry Sept 15, 2030","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves patent litigation regarding Teva's generic version of Jelmyto (mitomycin) for pyelocalyceal solution.","Teva granted non-exclusive license to sell generic Jelmyto starting September 15, 2030, if FDA approved.","All ongoing patent litigation between the parties in U.S. District Court for Delaware will be terminated.","Agreement is subject to review by U.S. Federal Trade Commission and U.S. Department of Justice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94548,"accession_number":"0001437749-26-015018","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q1 2026: ZUSDURI revenue $29.2M (+109% QoQ); net loss narrows to $0.47/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $51.0M, up 152% YoY on ZUSDURI launch and JELMYTO growth.","ZUSDURI net revenue $29.2M, 109% sequential growth; 256 unique prescribers as of March 31.","JELMYTO revenue $21.7M (+7% YoY); FY 2026 guidance reaffirmed at $97–101M.","Net loss $23.6M ($0.47/share) vs $43.8M ($0.92/share) in Q1 2025; cash $140.3M.","UGN-103 NDA submission on track for H2 2026; six-month durability data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":50959000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107009,"accession_number":"0001437749-26-006233","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen reports FY2025 net loss $153.5M; ZUSDURI launch net sales $15.8M; refinances debt at 8.25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue $109.8M (+21% YoY); JELMYTO net sales $94M (underlying demand +7%).","ZUSDURI net sales $15.8M in initial launch; 838 activated sites, 102 unique prescribers as of Dec 31, 2025.","Permanent J Code (J9282) effective Jan 1, 2026; launch acceleration expected.","Refinanced existing term loan: $200M funded at 8.25% fixed, new $50M tranche available until June 2027.","2026 guidance: JELMYTO net sales $97-101M; total operating expenses $240-250M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107008,"accession_number":"0001193125-26-084282","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"UroGen Pharma secures up to $250M loan at 8.25%; $200M funded to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tranche A of $200M funded on Feb 26, used to refinance $125M existing term loan and fund working capital.","Loan bears fixed 8.25% interest quarterly; principal repayments start Q1 2030 in four equal quarterly installments.","Second tranche of $50M available upon election by June 30, 2027, subject to conditions.","No financial covenants; collateral includes substantially all assets including intellectual property.","Loan matures 5 years from closing; prepayment subject to exit fee of 1% and makewhole within first year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123353,"accession_number":"0001437749-25-033466","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q3: ZUSDURI rev $1.8M, Oct estimate $4.5M; JELMYTO +13% YoY; net loss $33.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZUSDURI achieved net product revenue of $1.8M in Q3; October 2025 preliminary demand revenue estimate of $4.5M, with 592 activated sites and 54 prescribers since July launch.","JELMYTO net revenue $25.7M (+13% YoY underlying demand growth); full-year JELMYTO guidance unchanged at $94-98M, op expenses $215-225M.","Net loss of $33.3M ($0.69/share) vs $23.7M ($0.51) in Q3 2024; cash $127.4M as of Sept 30, 2025.","UGN-103 Phase 3 UTOPIA shows 77.8% CRR; FDA agrees to NDA submission plan; NDA expected H2 2026 with potential approval 2027.","UGN-301 (zalifrelimab) development discontinued; UroGen terminates license with Agenus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":71951000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140022,"accession_number":"0001437749-25-027874","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"UroGen shareholders approve 2.75M share increase under 2017 equity plan and new compensation policy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2017 Equity Incentive Plan, authorizing 2,750,000 additional ordinary shares.","Shareholders approved Amended and Restated Non-Employee Director and Officer Compensation Policy.","All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.","Advisory vote on executive compensation approved (18.85M for); one-year frequency for future say-on-pay votes selected.","PricewaterhouseCoopers LLP ratified as independent auditor with 32.9M votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140021,"accession_number":"0001437749-25-025242","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen reports Q2 loss of $49.9M; launches ZUSDURI after June FDA approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZUSDURI (mitomycin) FDA-approved June 12 for recurrent LG-IR-NMIBC; now commercially available.","JELMYTO Q2 net revenue $24.2M (+11% vs Q2 2024); FY guidance $94-98M unchanged.","Net loss $49.9M ($1.05/share) vs $33.4M ($0.82) in Q2 2024; operating loss $41.4M.","Cash and marketable securities $161.6M at June 30, 2025.","Enrollment complete in Phase 3 UTOPIA trial for next-gen mitomycin UGN-103."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":44469000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140020,"accession_number":"0001193125-25-155503","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"UroGen awards special bonuses totaling $845K to CEO, CFO, GC for ZUSDURI FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Elizabeth Barrett receives $645,000; CFO Chris Degnan and GC Jason Smith each get $100,000.","Bonuses approved June 30, 2025, for leadership leading to FDA approval of ZUSDURI for recurrent low-grade intermediate risk NMIBC.","ZUSDURI is a novel therapy for non-muscle invasive bladder cancer (NMIBC).","One-time special awards; no recurrence or changes to base compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157636,"accession_number":"0001193125-25-140339","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves UroGen Pharma's ZUSDURI (mitomycin) for recurrent LG-IR-NMIBC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved ZUSDURI (mitomycin) for adults with recurrent low-grade intermediate-risk NMIBC on June 12, 2025.","Phase 3 ENVISION trial: 78% achieved complete response at 3 months; 79% of those maintained at 12 months.","Expected commercial availability in the U.S. on or around July 1, 2025.","Common adverse reactions include increased creatinine, dysuria, hematuria; serious reactions in 12% of patients.","Post-marketing commitment: ongoing ENVISION trial to further characterize clinical benefit; annual duration of response updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157635,"accession_number":"0001437749-25-015955","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Pharma Q1 2025: JELMYTO revenue $20.3M, net loss widens to $43.8M; UGN-102 PDUFA June 13","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["JELMYTO net sales $20.3M (+8% YoY); underlying demand grew 12%.","Net loss of $43.8M ($0.92 per share) vs $32.3M ($0.87) in Q1 2024.","Cash and marketable securities $200.4M; FY2025 JELMYTO revenue guidance unchanged at $94–$98M.","UGN-102 NDA under FDA review; PDUFA target action date June 13, 2025; ODAC meeting May 21.","UGN-501 acquisition from IconOVir expensed; UGN-103 Phase 3 UTOPIA trial enrollment to complete mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":20254000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176011,"accession_number":"0001437749-25-006757","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen reports Q4/FY2024: JELMYTO rev $90.4M; net loss $126.9M; guides FY2025 rev $94-98M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["UGN-102 NDA under FDA review; PDUFA June 13, 2025; 18-month DOR 80.6% in Phase 3 ENVISION trial.","JELMYTO net product revenue $90.4M in FY2024, up 9% YoY; underlying demand revenue grew 12% (FY) and 15% (Q4).","Net loss Q4 2024 $37.5M ($0.80/share) vs $26.0M ($0.72/share) in Q4 2023; FY net loss $126.9M ($2.96/share) vs $102.2M ($3.55/share).","FY2025 guidance: JELMYTO revenue $94-98M; operating expenses $215-225M (incl. $11-14M share-based comp).","Cash, equivalents and marketable securities $241.7M at Dec 31, 2024, up from $141.5M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176010,"accession_number":"0001193125-25-030143","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"UroGen acquires ICVB-1042 assets from IconOVir for shares, milestone, and royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["UroGen issued 374,843 ordinary shares (worth $4.0M) to IconOVir as upfront consideration.","UroGen agreed to pay $15.0M cash milestone on cumulative global net sales of ICVB-1042 products.","UroGen will pay low single-digit royalties on worldwide net sales of ICVB Products.","Entities affiliated with Chair Arie Belldegrun hold promissory notes entitling them to ~28.3% of purchase price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176009,"accession_number":"0001193125-25-005649","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"UroGen Pharma furnishes January 2025 corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation reiterates UGN-102 PDUFA target date of June 13, 2025 and planned ODAC meeting.","Highlights ongoing Phase 3 UTOPIA study for UGN-103 and planned Phase 3 for UGN-104.","No new financial data or material changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192934,"accession_number":"0001193125-24-251712","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q3 revenue $25.2M, net loss $23.7M; UGN-102 PDUFA June 2025; cuts FY revenue view","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["JELMYTO Q3 net product revenue $25.2M (+21% YoY from $20.9M).","Net loss $23.7M ($0.55/share) vs $21.9M ($0.68/share) in Q3 2023.","NDA for UGN-102 accepted; PDUFA target action date June 13, 2025.","Full-year 2024 JELMYTO revenue expected below prior guidance low end; still low double-digit YoY growth.","Cash, equivalents, marketable securities $254.2M as of Sept 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":65833000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192933,"accession_number":"0001193125-24-234808","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"UroGen Pharma appoints Christopher Degnan as CFO; Don Kim resigns effectively Oct 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Don Kim resigned as CFO, principal financial and accounting officer effective Oct 8, 2024; will provide part-time consulting through Apr 28, 2025 for $36,260.","Kim receives 9 months base salary continuation, $217,590 lump sum (2024 target bonus), and COBRA reimbursement for 9 months.","Christopher Degnan appointed CFO effective Oct 8; prior CFO of Galera Therapeutics and Verrica Pharmaceuticals.","Degnan receives $500,000 annual base salary, 50% target bonus, and inducement equity: option for 74,142 shares at $13.11 and 13,450 RSUs vesting over 3 years.","Severance terms for Degnan include 6 months base salary, pro-rata bonus, and accelerated vesting of 8.33% of equity on qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209314,"accession_number":"0001193125-24-224801","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"UroGen Pharma draws $25M Tranche C loan under credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $25M third tranche loan on Sept 23, 2024; proceeds for general corporate and working capital needs.","Interest rate: 3-month SOFR + 7.25% + 0.26161% p.a., floor 2.50%, payable quarterly.","Matures Mar 16, 2027, extended to Mar 16, 2028 if FDA approves UGN-102 by June 30, 2025.","Repayment in four equal quarterly installments starting June 30, 2026 (or June 30, 2027 if FDA condition met).","Loan is secured by substantially all of the credit parties' tangible and intangible assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209313,"accession_number":"0001193125-24-218868","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Fred E. Cohen resigns from UroGen Pharma board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fred E. Cohen resigned as director on Sept 12, 2024.","Resignation is not due to any disagreement with the company.","No replacement director has been announced.","Dr. Cohen's departure is effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209312,"accession_number":"0001193125-24-200993","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"UroGen Pharma submits NDA to FDA for UGN-102 for low-grade intermediate-risk NMIBC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed NDA submission for UGN-102 to the U.S. FDA.","UGN-102 is intended for low-grade intermediate-risk non-muscle invasive bladder cancer treatment.","Regulatory submission marks a key milestone toward potential approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209311,"accession_number":"0001193125-24-199425","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen ahead of schedule completing UGN-102 NDA; Q2 revenue $21.8M, net loss $33.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["UGN-102 NDA completion imminent; potential FDA decision as early as Q1 2025 assuming priority review.","Q2 JELMYTO net revenue $21.8M (+3% YoY); full-year revenue expected at lower end of guidance range.","Q2 net loss $33.4M ($0.91/share) vs $24.1M ($1.03/share) in Q2 2023; operating loss $25.8M.","Cash & marketable securities $241.3M at June 30; June public offering raised $107.5M gross.","Full-year operating expenses expected at higher end of guidance; R&D $15.4M, SG&A $30.1M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":40629000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209310,"accession_number":"0001193125-24-197008","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"UroGen shareholders elect directors and approve compensation policy and equity plan amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected with over 24M votes for each; broker non-votes 6.75M.","2024 Compensation Policy approved: 22.4M for, 3.4M against, 513K abstentions, 6.75M broker non-votes.","Amendment to 2017 Equity Plan adding 800K shares approved: 22.7M for, 3.1M against, 548K abstentions.","Advisory vote on named executive officer compensation passed: 22.6M for, 3.1M against, 553K abstentions.","PricewaterhouseCoopers LLP ratified as auditor: 33.0M for, 8,345 against, 7,053 abstentions; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227290,"accession_number":"0001193125-24-163498","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"UroGen Pharma prices $107.5M public offering of 5M shares at $17.50, plus pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering: 5,000,000 ordinary shares at $17.50/share plus 1,142,857 pre-funded warrants at $17.499 each.","Gross proceeds expected to be approximately $107.5 million before underwriting discounts and expenses.","Underwriters granted a 30-day option to purchase up to an additional 921,428 ordinary shares.","Closing expected on June 20, 2024, subject to customary conditions.","TD Cowen and Guggenheim Securities are joint book-running managers; Oppenheimer & Co. is lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227289,"accession_number":"0001193125-24-160413","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"UroGen reports positive DOR data from Phase 3 ENVISION trial for UGN-102 in bladder cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["12-month DOR KM estimate for CR patients: 82.3% (95% CI: 75.9%-87.1%); predicted median DOR of 40 months.","ENVISION met primary endpoint with 79.6% CR rate at 3 months; safety profile mild-to-moderate.","Rolling NDA submission to FDA for UGN-102 to complete Q3 2024; potential acceptance Q4 2024, approval Q1/Q2 2025.","If approved, UGN-102 would be first FDA-approved medicine for LG-IR-NMIBC; addressable market over $5B (82K patients, $16-19K/dose).","UGN-102 offers a non-surgical alternative to TURBT; ~68% of patients have 2+ recurrences and repeated TURBT carries adverse event risks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227288,"accession_number":"0001193125-24-136728","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q1 net loss $32.3M; JELMYTO revenue up 10% to $18.8M; UGN-102 NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.3M ($0.97/share) vs $30.2M ($1.30) in Q1 2023; JELMYTO revenue $18.8M, +10% YoY.","FY2024 guidance reiterated: JELMYTO revenue $95-102M; operating expenses $175-185M.","UGN-102 rolling NDA submission to complete Q3 2024; ENVISION 12-month DOR data event June 13.","IND accepted for UGN-103; Phase 3 in LG-IR-NMIBC planned for 2024.","Cash $164.5M; OLYMPUS post-hoc shows JELMYTO median duration of response 47.8 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":18781000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246170,"accession_number":"0001193125-24-067432","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Pharma FY2023: JELMYTO revenue $82.7M (+28% YoY), net loss narrows, UGN-102 NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year JELMYTO net revenue $82.7M, up ~28% YoY from $64.4M; Q4 revenue $23.5M (+30% YoY).","Net loss narrowed to $102.2M ($3.55/share) for FY2023 from $109.8M ($4.81/share) in 2022.","Rolling NDA for UGN-102 initiated Jan 2024; completion target Sep 2024, potential FDA decision Q1 2025.","Licensed next-gen mitomycin formulations (UGN-103/104) from medac with IP protection until Dec 2041.","Restructured Pharmakon loan: lower interest rate, deferred payback, up to $100M additional credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246169,"accession_number":"0001193125-24-056770","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"UroGen presents at TD Cowen conference; no material updates provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 for TD Cowen 44th Annual Health Care Conference on March 4, 2024.","Title slide states: 'Developing Innovative Medicines to Treat Urothelial Cancers'.","No specific financial, clinical, or guidance data included in the filing or exhibit excerpt.","Filing is procedural Regulation FD disclosure; no new material events reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246168,"accession_number":"0001193125-24-054393","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"UroGen receives Teva Paragraph IV notice challenging two Jelmyto patents expiring 2031","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Teva filed ANDA seeking FDA approval for a generic version of Jelmyto (mitomycin) for pyelocaliceal solution.","Teva alleges U.S. Patent Nos. 9,040,074 and 9,950,069 (expire January 2031) are invalid, unenforceable, or not infringed.","CEO Liz Barrett states UroGen is prepared and confident in the strength and breadth of its patent portfolio.","This is the first Paragraph IV challenge to Jelmyto; litigation under the Hatch-Waxman Act expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246167,"accession_number":"0001193125-24-026699","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"UroGen presents at Guggenheim Healthcare Talks on Feb 8, 2024; no specific facts in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished a corporate presentation under Item 7.01 for the Guggenheim Healthcare Talks Conference on February 8, 2024.","Presentation titled 'Developing Innovative Medicines to Treat Urothelial Cancers' – text of exhibit does not include detailed updates.","No financial results, pipeline milestones, or guidance changes disclosed in the filing.","UroGen's stock ticker is URGN; presentation is for investor audiences only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246166,"accession_number":"0001193125-24-009259","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"UroGen licenses medac's mitomycin formulation for RTGel combo; plans Phase 3 for UGN-103","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide royalty-free license from medac for 80 mg mitomycin + 640 mg urea formulation combined with RTGel.","Medac to manufacture and supply product; UroGen responsible for development, commercialization, and regulatory approvals.","Medac may terminate if US regulatory approval for a Combined Product is not obtained by June 30, 2029.","Phase 3 study for UGN-103 (next-gen UGN-102) planned for 2024 in low-grade intermediate-risk NMIBC.","IP protection expected through June 2035 (medac) and December 2041 (UroGen patent applications)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246165,"accession_number":"0001193125-24-000244","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"UroGen amends manufacturing pact for UGN-102; extends term to 2027, commits €4.4M for equipment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to manufacturing agreement with Cenexi extends initial term to April 1, 2027.","UroGen revised minimum annual quantity forecasts for bulk mitomycin purchases.","Company agreed to reimburse up to €4.4 million for dedicated capital equipment for UGN-102 production.","Amendment is in anticipation of potential approval and launch of UGN-102, a mitomycin product for low-grade upper tract urothelial cancer.","Parties will negotiate final terms on equipment purchase, installation, and validation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263619,"accession_number":"0001193125-23-276676","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q3 JELMYTO revenue $20.9M (+30% YoY); FDA agrees to rolling NDA for UGN-102","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["JELMYTO net product revenue $20.9M in Q3 2023, up ~30% from $16.1M in Q3 2022.","FDA agreed to rolling NDA for UGN-102 in LG-IR-NMIBC starting Jan 2024; ENVISION trial showed 79.2% CRR at 3 months.","Net loss improved to $21.9M ($0.68/sh) from $25.8M ($1.13/sh) in Q3 2022.","Cash and marketable securities $153.9M as of Sep 30, 2023; FY 2023 revenue guidance reiterated at $76-86M.","ATLAS trial met primary endpoint; 55% reduction in risk of recurrence/progression/death."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":59183000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280836,"accession_number":"0001193125-23-232477","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"UroGen Pharma shareholders approve 2017 Plan amendment, elect directors, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected eight directors including Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, and Fred E. Cohen.","Approved amendment to 2017 Equity Incentive Plan increasing authorized shares by 450,000.","Approved grant of Performance Stock Units to CEO under the amended plan (13,115,279 for, 3,363,390 against).","Advisory say-on-pay passed with 13,668,197 for, 3,118,618 against, 35,305 abstentions.","Ratified PricewaterhouseCoopers LLP as independent auditor for next fiscal year (22,507,002 for, 16,731 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280835,"accession_number":"0001193125-23-208139","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen reports record Q2 JELMYTO revenue of $21.1M, positive Phase 3 data for UGN-102","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 JELMYTO net revenue $21.1M (+27% YoY); net loss $24.1M ($1.03/share) vs $26.7M ($1.18) year ago.","ENVISION Phase 3 trial met primary endpoint: 79.2% complete response at 3 months in LG-IR-NMIBC patients.","ATLAS Phase 3 showed 55% reduction in recurrence/progression/death risk for UGN-102+TURBT vs TURBT alone.","Completed $120M private placement of ordinary shares and pre-funded warrants to support UGN-102 launch.","Cash and equivalents $55.3M at June 30, 2023, excluding $120M proceeds; FY revenue guidance $76-86M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":38331000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280834,"accession_number":"0001193125-23-195560","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"UroGen raises $120M from institutions; UGN-102 Phase 3 trials meet endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$120M gross proceeds from private placement at $9.54/share led by RA Capital and Great Point Partners.","ATLAS trial: UGN-102 reduced risk of recurrence/progression/death by 55% vs TURBT alone.","ENVISION trial: 79.2% complete response rate at 3 months for UGN-102.","Pre-funded warrants at $0.001/share, not expiring; closing expected July 28.","NDA submission for UGN-102 anticipated in 2024 pending additional data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280833,"accession_number":"0001193125-23-193453","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"UroGen appoints James A. Robinson Jr. to Board, increasing size to 9 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 8 to 9; Robinson appointed to fill vacancy and serve on Compliance Committee.","Initial option grant of 20,000 ordinary shares, vesting quarterly over 12 quarters.","Annual retainer of $40,000 plus $5,000 for Compliance Committee service.","Eligible for annual option grant of 10,000 shares at each annual shareholder meeting.","Standard indemnity agreement will be entered with Robinson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299476,"accession_number":"0001193125-23-141462","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Pharma Q1 2023 JELMYTO revenue $17.2M (+27% YoY); net loss $30.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["JELMYTO net product revenue $17.2M, up ~27% from $13.6M in Q1 2022.","Net loss $30.2M ($1.30 per share) vs $28.4M ($1.25 per share) in Q1 2022.","Cash and marketable securities $75.2M as of March 31, 2023.","Reiterated FY 2023 JELMYTO revenue guidance $76-86M; operating expenses $135-145M.","Topline data from ENVISION and ATLAS trials for UGN-102 expected summer 2023; NDA submission planned for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":17192000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319625,"accession_number":"0001193125-23-076682","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Pharma reports FY2022 JELMYTO revenue of $64.4M (+34% YoY); guides FY2023 revenue $76-86M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["JELMYTO net revenue for FY2022: $64.4M, up 34% from $48.0M in FY2021; Q4 revenue: $18.1M.","Net loss for FY2022: $109.2M ($4.79/share) vs $110.8M ($4.96/share) in FY2021; cash ~$100M.","UGN-102 Phase 3 ENVISION fully enrolled (~220 patients); topline data for ENVISION and ATLAS expected mid-2023; NDA submission targeted for 2024.","FY2023 guidance: JELMYTO revenue $76-86M; operating expenses $135-145M; cash expected to fund operations into H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337829,"accession_number":"0001193125-22-281988","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q3 JELMYTO revenue up 41% to $16.1M; net loss narrows to $25.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["JELMYTO net product revenue $16.1M (+41% YoY); operating loss improved to $18.1M from $23.4M.","Net loss $25.8M ($1.13/share) vs $30.2M ($1.35/share) in Q3 2021; cash, cash equivalents and marketable securities $95.9M.","ENVISION Phase 3 trial for UGN-102 enrollment completion expected as soon as end of Nov 2022; NDA submission anticipated H1 2024.","FDA authorized extension of JELMYTO in-use period from 8 to 96 hours following reconstitution.","Appointed Dr. Leana S. Wen and Dan Wildman to the Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":46265000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337828,"accession_number":"0001193125-22-280620","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"UroGen Pharma appoints Daniel G. Wildman to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel G. Wildman appointed to fill a board vacancy effective November 8, 2022.","Initial option grant of 20,000 ordinary shares, vesting in equal quarterly installments over 12 quarters.","Annual retainer of $40,000 for board service plus $5,000 for service on the Compliance Committee.","Eligible for annual option grant of 10,000 ordinary shares at each annual shareholder meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337827,"accession_number":"0001193125-22-266722","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"UroGen Pharma draws $25M second tranche from $100M BioPharma Credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M Tranche B Loan requested Oct 21, 2022; funding expected Dec 16, 2022.","Interest rate: 8.25% + 3-month LIBOR (floor 1.25%); matures March 2027.","Proceeds to be used for general corporate and working capital requirements.","Repayment in four equal quarterly payments starting after 17th quarter anniversary of Tranche A closing.","Prepayment premiums: 3% if before 3rd anniversary, 2% if 3-4 yrs, 1% if after 4 yrs; makewhole within 2 yrs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355187,"accession_number":"0001437749-22-022160","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"UroGen appoints Dr. Leana Wen to board and audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Wen appointed to fill vacancy; term runs until 2023 annual meeting.","Received initial option for 20,000 ordinary shares vesting quarterly over 12 quarters.","Annual retainer of $40,000 for board service plus $7,500 for audit committee.","Eligible for annual option grant of 10,000 ordinary shares at each shareholder meeting.","Company entered standard director indemnity agreement with Dr. Wen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355186,"accession_number":"0001193125-22-218026","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q2 Jelmyto revenue $16.6M (+28% YoY); reaffirms FY22 guidance $70-80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 Jelmyto net revenue $16.6M, up 22% QoQ and 28% YoY from $13.0M.","Net loss $26.7M ($1.18/share) vs $26.2M ($1.17/share) in Q2 2021.","Cash and marketable securities $112.4M as of June 30, 2022.","Reaffirms FY2022 Jelmyto revenue guidance of $70-80M; reduces operating expense forecast to $130-140M.","Enrollment in Phase 3 ENVISION trial for UGN-102 on track for completion by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":30168000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373295,"accession_number":"0001437749-22-014892","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"UroGen shareholders reject say-on-pay and compensation policy; approve equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory vote on executive compensation failed: 5.7M against vs 4.2M for.","Amendment to compensation policy under Israeli law not approved: 2.5M for, 4.9M against.","Equity plan amendment (increase by 400K shares) approved narrowly: 5.3M for, 4.5M against.","PricewaterhouseCoopers ratified as independent auditor with 14.2M votes for.","All six director nominees elected, with Arie Belldegrun receiving 7.5M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373294,"accession_number":"0001193125-22-145810","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UroGen Q1 Jelmyto revenue $13.6M (+81% YoY); net loss $28.4M; cash $137.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jelmyto net revenue $13.6M, +81% vs Q1 2021 ($7.5M).","Net loss $28.4M ($1.25/shr) vs $25.9M ($1.17/shr) a year ago.","Cash, cash equivalents & marketable securities $137.1M at Mar 31, up from $89.8M.","Reiterated FY2022 Jelmyto revenue guidance $70-80M and operating expenses $140-160M.","Phase 3 ENVISION trial of UGN-102 enrollment expected to complete by end 2022; NDA submission projected 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":13564000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392044,"accession_number":"0001193125-22-080081","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"UroGen Pharma CFO resigns; reports FY2021 Jelmyto revenue $48M, net loss $110.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CFO Molly Henderson resigns effective March 25, 2022; replaced by Dong Kim (VP Finance).","FY2021 Jelmyto net product revenue $48.0M, up 307% YoY; Q4 revenue $16.2M, up 42% QoQ.","FY2021 net loss $110.8M ($4.96/share) vs $128.5M loss in prior year.","2022 revenue guidance $70-80M; operating expenses guided $140-160M; RTW financing expense $22-26M.","Closed $75M tranche of up to $100M senior secured term loan facility with Pharmakon Advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392043,"accession_number":"0001193125-22-068800","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"UroGen Pharma enters $100M term loan facility with BPCR Limited Partnership","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term loans up to $100M; Tranche A $75M at closing, Tranche B $25M optional by Dec 31, 2022.","Interest rate 8.25% + 3-month LIBOR (floor 1.25%); quarterly interest; principal amortization starts after 17th quarter.","Secured by substantially all assets; no financial covenants; prepayment premiums (3%/2%/1%) and makewhole provisions.","Proceeds for general corporate and working capital; loan matures 5 years from Tranche A closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410365,"accession_number":"0001193125-21-329000","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"UroGen Q3 Jelmyto rev $11.4M; ends Allergan pact; shifts UGN-102 trial to single-arm Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2021 net product revenue $11.4M; net loss $30.2M ($1.35/share) vs $28.8M loss ($1.31) in Q3 2020.","Full-year 2021 revenue guidance $47-51M; operating expense guidance reduced to $137-142M from $155-165M.","Ceased enrollment in ATLAS Phase 3 for UGN-102; new single-arm Phase 3 trial planned for early 2022; NDA submission expected 2024.","Mutually terminated license agreement with Allergan effective November 11, 2021.","Cash and equivalents $110.3M as of Sep 30; Jelmyto site activations up 73% since August 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":31868000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410364,"accession_number":"0001193125-21-326173","cik":1668243,"company_name":"UroGen Pharma Ltd.","ticker":"URGN","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"UroGen to start new Phase 3 study for UGN-102; stops ATLAS enrollment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New single-arm Phase 3 pivotal study for UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cancer expected to start early 2022, enrolling ~220 patients at 90 sites.","ATLAS trial enrollment halted; patients already enrolled may remain until completion.","Company believes new study design increases regulatory success probability; NDA submission for UGN-102 remains on track for 2024.","UGN-301: non-human primate toxicity studies underway; multi-arm Phase 1 study planned early 2022 with combination approaches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1376880000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-10T23:59:59+00:00|410364"}